Adaptive Biotechnologies Corp (NASDAQ:ADPT) has a beta value of 1.48 and has seen 0.46 million shares traded in the recent trading session. The company, currently valued at $986.57M, closed the recent trade at $6.68 per share which meant it lost -$0.1 on the day or -1.40% during that session. The ADPT stock price is -5.84% off its 52-week high price of $7.07 and 65.87% above the 52-week low of $2.28. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.12 million shares traded. The 3-month trading volume is 1.21 million shares.

The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is Hold stock at the moment, with a recommendation rating of 1.50. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 11 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.

Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information

Sporting -1.40% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADPT stock price touched $6.68 or saw a rise of 3.61%. Year-to-date, Adaptive Biotechnologies Corp shares have moved 36.43%, while the 5-day performance has seen it change -0.37%. Over the past 30 days, the shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) have changed 31.59%. Short interest in the company has seen 9.58 million shares shorted with days to cover at 6.68.

Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 52.29% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $18.0. In that case, then, we find that the latest price level in today’s session is -169.46% off the targeted high while a plunge would see the stock lose 25.15% from the levels at last check today.

Adaptive Biotechnologies Corp (ADPT) estimates and forecasts

Figures show that Adaptive Biotechnologies Corp shares have outperformed across the wider relevant industry. The company’s shares have gained 117.05% over the past 6 months, with this year growth rate of 18.84%, compared to 17.20% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -32.91% over the past 5 years.

ADPT Dividends

Adaptive Biotechnologies Corp is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders

Insiders own 1.93% of the company shares, while shares held by institutions stand at 93.92% with a share float percentage of 95.77%. Investors are also buoyed by the number of investors in a company, with Adaptive Biotechnologies Corp having a total of 249.0 institutions that hold shares in the company. The top two institutional holders are VIKING GLOBAL INVESTORS LP with over 29.99 million shares worth more than $108.58 million. As of 2024-06-30, VIKING GLOBAL INVESTORS LP held 20.5736% of shares outstanding.

The other major institutional holder is RUBRIC CAPITAL MANAGEMENT LP, with the holding of over 14.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $50.68 million and represent 9.603% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard Total Stock Market Index Fund. As of Oct 31, 2024, the former fund manager holds about 7.63% shares in the company for having 11.26 shares of worth $75.08 million while later fund manager owns 4.19 shares of worth $27.96 million as of Sep 30, 2024, which makes it owner of about 2.84% of company’s outstanding stock.